1
|
Reig-López J, Cuquerella-Gilabert M, Bandín-Vilar E, Merino-Sanjuán M, Mangas-Sanjuán V, García-Arieta A. Bioequivalence risk assessment of oral formulations containing racemic ibuprofen through a chiral physiologically based pharmacokinetic model of ibuprofen enantiomers. Eur J Pharm Biopharm 2024; 199:114293. [PMID: 38641229 DOI: 10.1016/j.ejpb.2024.114293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Revised: 03/26/2024] [Accepted: 04/15/2024] [Indexed: 04/21/2024]
Abstract
The characterization of the time course of ibuprofen enantiomers can be useful in the selection of the most sensitive analyte in bioequivalence studies. Physiologically based pharmacokinetic (PBPK) modelling and simulation represents the most efficient methodology to virtually assess bioequivalence outcomes. In this work, we aim to develop and verify a PBPK model for ibuprofen enantiomers administered as a racemic mixture with different immediate release dosage forms to anticipate bioequivalence outcomes based on different particle size distributions. A PBPK model incorporating stereoselectivity and non-linearity in plasma protein binding and metabolism as well as R-to-S unidirectional inversion has been developed in Simcyp®. A dataset composed of 11 Phase I clinical trials with 54 scenarios (27 per enantiomer) and 14,452 observations (7129 for R-ibuprofen and 7323 for S-ibuprofen) was used. Prediction errors for AUC0-t and Cmax for both enantiomers fell within the 0.8-1.25 range in 50/54 (93 %) and 42/54 (78 %) of scenarios, respectively. Outstanding model performance, with 10/10 (100 %) of Cmax and 9/10 (90 %) of AUC0-t within the 0.9-1.1 range, was demonstrated for oral suspensions, which strongly supported its use for bioequivalence risk assessment. The deterministic bioequivalence risk assessment has revealed R-ibuprofen as the most sensitive analyte to detect differences in particle size distribution for oral suspensions containing 400 mg of racemic ibuprofen, suggesting that achiral bioanalytical methods would increase type II error and declare non-bioequivalence for formulations that are bioequivalent for the eutomer.
Collapse
Affiliation(s)
- Javier Reig-López
- Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Valencia, Spain; Interuniversity Research Institute for Molecular Recognition and Technological Development, University of Valencia-Polytechnic University of Valencia, Spain
| | - Marina Cuquerella-Gilabert
- Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Valencia, Spain; Interuniversity Research Institute for Molecular Recognition and Technological Development, University of Valencia-Polytechnic University of Valencia, Spain; Simulation Department, Empresarios Agrupados Internacional S.A., Madrid, Spain
| | - Enrique Bandín-Vilar
- Pharmacy Department, University Clinical Hospital Santiago de Compostela (CHUS), Spain; Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), Spain; Pharmacology, Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy, University of Santiago de Compostela (USC), Spain
| | - Matilde Merino-Sanjuán
- Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Valencia, Spain; Interuniversity Research Institute for Molecular Recognition and Technological Development, University of Valencia-Polytechnic University of Valencia, Spain
| | - Víctor Mangas-Sanjuán
- Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Valencia, Spain; Interuniversity Research Institute for Molecular Recognition and Technological Development, University of Valencia-Polytechnic University of Valencia, Spain.
| | - Alfredo García-Arieta
- Área de Farmacocinética y Medicamentos Genéricos, División de Farmacología y Evaluación Clínica, Departamento de Medicamentos de Uso Humano, Agencia Española de Medicamentos y Productos Sanitarios, Spain
| |
Collapse
|
2
|
El-Ashmawy AA, Abdelfattah FM, Emara LH. Novel Glyceryl Monostearate- and Polyethylene Glycol 6000-Based Ibuprofen Pellets Prepared by Hot-Melt Extrusion: Evaluation and Stability Assessment. J Pharm Innov 2022. [DOI: 10.1007/s12247-022-09647-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Abstract
Purpose
To prepare stable sustained-release (SR) pellets, containing high ibuprofen (IBU) loading, by hot-melt extrusion (HME) technique using polyethylene glycol 6000 (PEG 6000) and glyceryl monostearate (GMS).
Methods
HME pellets (60% w/w IBU) were prepared using PEG 6000, GMS, and mixture of both polymers (1:1). Stability studies were performed under stress conditions (40 °C and relative humidity “RH” of 75%) for 6 months and at room temperature for 12 months. Fresh and stored IBU pellets were evaluated by drug content (HPLC), release rate study (USP apparatus IV), DSC, and XRD.
Results
HME succeeded to produce SR-IBU pellets with high drug loading. PEG 6000 gave higher IBU release rate and relatively unstable formula after storage. PEG 6000/GMS mixture gave prolonged IBU release up to 4 h with stable formula for 12 months at room temperature. While, IBU/GMS pellets gave SR profile up to 6 h and a stable formula under both testing conditions. These advantages of IBU/GMS pellets could be an excellent candidate for SR-IBU product. DSC and XRD analysis data (enthalpy and counts) for IBU and polymers gave a mirror image for IBU release profiles of the studied HME pellets, for both fresh and stored samples.
Conclusion
Stable SR-IBU/GMS HME pellets with high IBU loading (60% w/w) were successfully produced, for the first time, without any other excipients.
Collapse
|
3
|
Edison PE, Chen S, Yeo CL, Allen JC, Poon WB, Baral VR, Chowbay B. Pharmacokinetics of oral versus intravenous ibuprofen for closure of patent ductus arteriosus: A pilot randomised controlled study. J Paediatr Child Health 2022; 58:397-403. [PMID: 34477275 DOI: 10.1111/jpc.15720] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Revised: 08/08/2021] [Accepted: 08/16/2021] [Indexed: 01/12/2023]
Abstract
AIM This pilot study aimed to compare the pharmacokinetic profiles of oral (PO) and intravenous (IV) ibuprofen for treatment of patent ductus arteriosus (PDA) in preterm neonates. METHODS In a single-centre, parallel, randomised open-label trial, neonates ≤35 weeks, weight <1800 g with haemodynamically significant PDA during the first week of life were recruited between June 2017 and February 2019 and randomised to receive either PO or IV ibuprofen at standard dosage of 10, 5 and 5 mg/kg every 24 h for three consecutive days. Plasma concentrations of ibuprofen were quantified using a validated high-performance liquid chromatography method and pharmacokinetic parameters were calculated. Treatment outcomes were recorded. RESULTS Eleven neonates participated in the trial, six and five patients receiving PO and IV ibuprofen, respectively. Pharmacokinetic analysis reveals similar ibuprofen exposure levels in treatment groups. Median dose- and weight-normalised Cmax values of PO and IV groups were 2.12 and 2.53 g/mL respectively (P = 0.082) and median AUC0-24 levels were comparable (PO: 34.6 g*h/mL vs. IV: 50.7.6 g*h/mL, P = 0.25). CONCLUSION This exploratory study demonstrates comparable pharmacokinetics of PO and IV formulations of ibuprofen in preterm neonates. Larger prospective studies are required to validate these findings.
Collapse
Affiliation(s)
- Priyantha Ebenezer Edison
- Department of Neonatal & Developmental Medicine, The Academia, Singapore General Hospital, Singapore, Singapore
| | - Sylvia Chen
- Clinical Pharmacology Laboratory, Division of Cellular & Molecular Research, National Cancer Centre, Singapore General Hospital, Singapore, Singapore
| | - Cheo Lian Yeo
- Department of Neonatal & Developmental Medicine, The Academia, Singapore General Hospital, Singapore, Singapore
| | - John C Allen
- Centre for Quantitative Medicine, Office of Clinical Sciences, Duke NUS Medical School, Singapore, Singapore
| | - Woei Bing Poon
- Department of Neonatal & Developmental Medicine, The Academia, Singapore General Hospital, Singapore, Singapore
| | - Vijayendra R Baral
- Department of Neonatal & Developmental Medicine, The Academia, Singapore General Hospital, Singapore, Singapore
| | - Balram Chowbay
- Clinical Pharmacology Laboratory, Division of Cellular & Molecular Research, National Cancer Centre, Singapore General Hospital, Singapore, Singapore.,Office of Clinical Sciences, Duke-NUS Medical School, Singapore, Singapore
| |
Collapse
|
4
|
Saiz-Rodríguez M, Valdez-Acosta S, Borobia AM, Burgueño M, Gálvez-Múgica MÁ, Acero J, Cabaleiro T, Muñoz-Guerra MF, Puerro M, Llanos L, Martínez-Pérez D, Ochoa D, Carcas AJ, Abad-Santos F. Influence of Genetic Polymorphisms on the Response to Tramadol, Ibuprofen, and the Combination in Patients With Moderate to Severe Pain After Dental Surgery. Clin Ther 2021; 43:e86-e102. [PMID: 33812699 DOI: 10.1016/j.clinthera.2021.03.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Revised: 02/22/2021] [Accepted: 03/08/2021] [Indexed: 10/21/2022]
Abstract
PURPOSE We aimed to elucidate the influence on analgesic effect of genetic polymorphisms in enzymes responsible for biotransformation of tramadol and ibuprofen or other possible genes involved in their mechanism of action. METHODS The study population comprised 118 patients from a multicenter, randomized, double-blind, placebo-controlled, Phase III clinical trial that assessed the analgesic efficacy and tolerability of a single dose of ibuprofen (arginine)/tramadol 400/37.5 mg compared with ibuprofen arginine 400 mg alone, tramadol 50 mg alone, and placebo in patients with moderate to severe pain after dental surgery. We analyzed 32 polymorphisms in the cytochrome P450 (CYP) enzymes COMT, ABCB1, SLC22A1, OPRM1, and SLC22A1. FINDINGS We did not find any statistically significant difference among CYP2C9 phenotypes related to ibuprofen response, although CYP2C9 poor metabolizers had a longer effect (higher pain relief at 6 hours). Likewise, we did not find any statistically significant difference among PTGS2 genotypes, contradicting previously publications. IMPLICATIONS There was not a clear effect of CYP2D6 phenotype on tramadol response, although CYP2D6 poor metabolizers had a slower analgesic effect. Concerning the transport of CYP2D6, we observed a better response in individuals carrying ABCB1 mutated alleles, which might correlate with higher tramadol plasma levels. Finally, we found a statistically significant better response in patients carrying the OPRM1 A118G G allele, which contradicts the previous reports. Measuring the active metabolite O-desmethyl-tramadol formation would be of great importance to better evaluate this association because O-desmethyl-tramadol has a higher μ-opioid receptor affinity compared with the parent drug. EudraCT.ema.europa.eu identifier: 2013-004637-33.
Collapse
Affiliation(s)
- Miriam Saiz-Rodríguez
- Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Facultad de Medicina, Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain; Research Unit, Fundación Burgos por la Investigación de la Salud, Hospital Universitario de Burgos, Burgos, Spgrain
| | - Sarahí Valdez-Acosta
- Ethics Committee for Research with medicinal products and Clinical Research Unit, Fundación de investigación Biomédica, Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain
| | - Alberto M Borobia
- Clinical Pharmacology Department, La Paz University Hospital, School of Medicine, Universidad Autónoma de Madrid, Spain
| | - Miguel Burgueño
- Department of Oral and Maxillofacial Surgery, Hospital Universitario La Paz, Madrid, Spain
| | - María Ángeles Gálvez-Múgica
- Clinical Pharmacology Department, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain
| | - Julio Acero
- Department of Oral and Maxillofacial Surgery, Hospital Universitario Ramón y Cajal, University of Alcalá, Madrid, Spain
| | - Teresa Cabaleiro
- Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Facultad de Medicina, Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain
| | - Mario Fernando Muñoz-Guerra
- Department of Oral and Maxillofacial Surgery, University Hospital La Princesa, Universidad Autónoma de Madrid, Madrid, Spain; Department of Oral and Maxillofacial Surgery, University Hospital Montepríncipe, San Pablo CEU University, Madrid, Spain
| | - Miguel Puerro
- Clinical Pharmacology Department, Hospital Central de la Defensa Gomez Ulla, Departamento de Ciencias Biomédicas, Universidad de Alcalá, Madrid, Spain
| | - Lucia Llanos
- Clinical Research Unit, Hospital Universitario Fundación Jiménez Diaz, Madrid, Spain
| | - Dolores Martínez-Pérez
- Department of Oral and Maxillofacial Surgery, Hospital Universitario Fundación Jiménez Diaz, Madrid, Spain
| | - Dolores Ochoa
- Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Facultad de Medicina, Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain; UICEC Hospital Universitario de La Princesa, Plataforma SCReN (Spanish Clinical Reseach Network), Instituto de Investigación Sanitaria La Princesa, Madrid, Spain
| | - Antonio J Carcas
- Clinical Pharmacology Department, La Paz University Hospital, School of Medicine, Universidad Autónoma de Madrid, Spain
| | - Francisco Abad-Santos
- Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Facultad de Medicina, Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain; UICEC Hospital Universitario de La Princesa, Plataforma SCReN (Spanish Clinical Reseach Network), Instituto de Investigación Sanitaria La Princesa, Madrid, Spain.
| |
Collapse
|
5
|
Matji A, Vargas E, Carvajal L, Terleira AI, Portolés A, Garcia-Arieta A, Torrado JJ, Serrano DR. Effect of enantiomerism on the bioequivalence of a new ibuprofen 600-mg tablet formulation obtained by roller compaction. Chirality 2019; 32:185-190. [PMID: 31755587 DOI: 10.1002/chir.23148] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2019] [Revised: 10/04/2019] [Accepted: 10/14/2019] [Indexed: 11/07/2022]
Abstract
The bioequivalence of a new ibuprofen 600-mg film-coated tablet obtained by roller compaction was studied in a crossover study with 22 healthy volunteers. Bioequivalence was analyzed based on (a) the S-enantiomer, (b) the R-enantiomer, and (c) the sum of both enantiomers (representing the results of an achiral assay). The bioequivalence conclusion for ibuprofen products should be based not only on AUC and Cmax but also on tmax since tmax is related to the onset of action. However, it is not possible to ensure if bioequivalence has been demonstrated for tmax as regulators have not defined the acceptance range for the difference between medians of tmax in those cases, where tmax is clinically relevant. In this study, it was possible to conclude bioequivalence for tmax based on S-ibuprofen, though this conclusion might be questioned if the decision is based on R-ibuprofen or the achiral method.
Collapse
Affiliation(s)
- Antonio Matji
- Pharmaceutics and Food Technology, Complutense University Madrid, Madrid, Spain
| | - Emilio Vargas
- Clinical Pharmacology Service, Pharmacology, Hospital Clínico San Carlos, Complutense University of Madrid/IdISSC, Madrid, Spain
| | - Luis Carvajal
- Pharmaceutics and Food Technology, Complutense University Madrid, Madrid, Spain
| | - Ana Isabel Terleira
- Clinical Pharmacology Service, Pharmacology, Hospital Clínico San Carlos, Complutense University of Madrid/IdISSC, Madrid, Spain
| | - Antonio Portolés
- Clinical Pharmacology Service, Pharmacology, Hospital Clínico San Carlos, Complutense University of Madrid/IdISSC, Madrid, Spain
| | - Alfredo Garcia-Arieta
- Pharmacology and Clinical Evaluation, Human Use Medicines, Spanish Agency for Medicines and Health Care Products, Madrid, Spain
| | - Juan J Torrado
- Pharmaceutics and Food Technology, Complutense University Madrid, Madrid, Spain
| | - Dolores R Serrano
- Pharmaceutics and Food Technology, Complutense University Madrid, Madrid, Spain
| |
Collapse
|
6
|
AKR1D1*36 C>T (rs1872930) allelic variant is associated with variability of the CYP2C9 genotype predicted pharmacokinetics of ibuprofen enantiomers - a pilot study in healthy volunteers. ACTA PHARMACEUTICA (ZAGREB, CROATIA) 2019; 69:399-412. [PMID: 31259734 DOI: 10.2478/acph-2019-0032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 02/18/2019] [Indexed: 01/19/2023]
Abstract
The relative contribution of CYP2C9 allelic variants to the pharmacokinetics (PK) of ibuprofen (IBP) enantiomers has been studied extensively, but the potential clinical benefit of pharmacogenetically guided IBP treatment is not evident yet. The role of AKR1D1*36C>T (rs 1872930) allelic variant in interindividual variability of CYP450 mediated drug metabolism was recently elucidated. A total of 27 healthy male subjects, volunteers in IBP single-dose two-way cross-over bioequivalence studies were genotyped for CYP2C9*2, CYP2C9*3 and AKR1D1*36 polymorphisms. The correlation between CYP2C9 and AKR1D1 genetic profile and the PK parameters for S-(+) and R-(-)-IBP was evaluated. Remarkable changes in the PK values pointing to reduced CYP2C9 enzyme activity were detected only in the CYP2C9*2 allelic variant carriers. Statistically significant association between the AKR1D1*36 allele and the increased IBP metabolism (low AUC0-t and 0-∞, high Cltot and short tmax values for both enantiomers) was observed in subjects carrying the CYP2C9 *1/*3 or CYP2C9*1/*1 genotype. The clinical value of concomitant CYP2C9 and AKR1D1 genotyping has to be further verified.
Collapse
|
7
|
Chiba K, Shimizu K, Kato M, Miyazaki T, Nishibayashi T, Terada K, Sugiyama Y. Estimation of Interindividual Variability of Pharmacokinetics of CYP2C9 Substrates in Humans. J Pharm Sci 2017; 106:2695-2703. [DOI: 10.1016/j.xphs.2017.04.021] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2017] [Revised: 04/05/2017] [Accepted: 04/10/2017] [Indexed: 01/10/2023]
|
8
|
Przejczowska-Pomierny K, Włodyka M, Cios A, Wyska E. Enantioselective analysis of ibuprofen enantiomers in mice plasma and tissues by high-performance liquid chromatography with fluorescence detection: Application to a pharmacokinetic study. Chirality 2017; 29:500-511. [DOI: 10.1002/chir.22715] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2016] [Revised: 04/23/2017] [Accepted: 04/26/2017] [Indexed: 11/10/2022]
Affiliation(s)
| | - Monika Włodyka
- Department of Pharmacokinetics and Physical Pharmacy; Jagiellonian University Medical College; Cracow Poland
| | - Agnieszka Cios
- Department of Pharmacokinetics and Physical Pharmacy; Jagiellonian University Medical College; Cracow Poland
| | - Elżbieta Wyska
- Department of Pharmacokinetics and Physical Pharmacy; Jagiellonian University Medical College; Cracow Poland
| |
Collapse
|
9
|
Influence of Sex and Food on the Bioavailability and the R-to-S Conversion of Ketoprofen Stereoisomers in Humans. Eur J Drug Metab Pharmacokinet 2017; 42:167-169. [DOI: 10.1007/s13318-016-0396-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
10
|
Stereoselective Conversion of Ketoprofen in Men Versus Women from Two Different Oral Dosage Formulations: Observations and Introspection of the Pharmacokinetic Data. Eur J Drug Metab Pharmacokinet 2017; 42:165-166. [PMID: 28101840 DOI: 10.1007/s13318-016-0395-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
11
|
Determination of ibuprofen enantiomers in human plasma by HPLC–MS/MS: validation and application in neonates. Bioanalysis 2016; 8:1237-50. [PMID: 27225837 DOI: 10.4155/bio-2016-0013] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Aim: An adaptive method to determine ibuprofen enantiomers with limited volume of plasma required is necessary for investigating PK of ibuprofen in neonates. Results: Enantiomer separation was achieved on a Lux cellulose 3 column with mobile phase consisting of methanol water (85:15, v/v) and formic acid (0.0075%) at isocratic rate of 0.2 ml/min. Calibration curve is linear for each enantiomer at the range of 0.1–60 μg/ml. Validation was conducted and results met requirements regarding to intra- and inter-run precision, accuracy and recovery. No matrix effect or interference was observed from neonatal plasma or comedications. Only 20 μl of plasma was requested in this study. Conclusion: This assay was specific and reliable to quantify ibuprofen enantiomers in neonate plasma.
Collapse
|
12
|
Suresh PS, Srinivas NR, Mullangi R. A concise review of the bioanalytical methods for the quantitation of sitagliptin, an important dipeptidyl peptidase-4 (DPP4) inhibitor, utilized for the characterization of the drug. Biomed Chromatogr 2016; 30:749-71. [DOI: 10.1002/bmc.3705] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2015] [Revised: 02/03/2016] [Accepted: 02/07/2016] [Indexed: 01/21/2023]
Affiliation(s)
- P. S. Suresh
- Jubilant Biosys; 2nd Stage, Industrial Suburb, Yeswanthpur Bangalore 560 022 India
| | | | - Ramesh Mullangi
- Jubilant Biosys; 2nd Stage, Industrial Suburb, Yeswanthpur Bangalore 560 022 India
| |
Collapse
|
13
|
Beloica S, Cvijić S, Bogataj M, Parojčić J. In vitro-in vivo-in silico approach in biopharmaceutical characterization of ibuprofen IR and SR tablets. Eur J Pharm Sci 2015; 75:151-9. [PMID: 25861718 DOI: 10.1016/j.ejps.2015.03.027] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2015] [Revised: 03/31/2015] [Accepted: 03/31/2015] [Indexed: 02/07/2023]
Abstract
Within the last decades, physiologically based pharmacokinetic models have emerged into a biopharmaceutical toolkit that has been proven useful in understanding how physicochemical, formulation and physiological factors affect oral drug absorption. The purpose of this study was to develop a drug specific physiologically based pharmacokinetic model that will allow mechanistic interpretation of oral absorption from dosage forms exhibiting different in vitro and different in vivo performance (i.e. immediate release and sustained release tablets) and identification of bioperformance dissolution testing. Ibuprofen was chosen to be used for the "proof of concept" considering it is well characterised and the necessary physicochemical, biopharmaceutical and pharmacokinetic properties for model development could be found in the literature. Gastrointestinal simulation technology implemented in Simcyp® was successful in estimating ibuprofen oral absorption. The developed model exhibited good generalisation ability for the dosage forms studied. The obtained results indicate that the model was sensitive to input kinetics represented by the in vitro drug release profiles obtained under various dissolution conditions. According to the obtained results, reciprocating cylinder apparatus with biorepresentative change in media pH might be considered as bioperformance dissolution in the case of the two ibuprofen SR products studied. These results further justify the use of integrated in vitro-in vivo-in silico approach in estimating bioperformance of oral solid dosage forms.
Collapse
Affiliation(s)
- Sofija Beloica
- Department of Pharmaceutical Technology and Cosmetology, University of Belgrade, Faculty of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, Serbia.
| | - Sandra Cvijić
- Department of Pharmaceutical Technology and Cosmetology, University of Belgrade, Faculty of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, Serbia.
| | - Marija Bogataj
- Department of Biopharmacy and Pharmacokinetics, University of Ljubljana, Faculty of Pharmacy, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia.
| | - Jelena Parojčić
- Department of Pharmaceutical Technology and Cosmetology, University of Belgrade, Faculty of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, Serbia.
| |
Collapse
|
14
|
Abstract
Stereochemical factors are known to play a significant role in the metabolism of drugs and other xenobiotics. Following Prelog's lead, types of metabolic stereoselectivity can be categorized as (i) substrate stereoselectivity (the differential metabolism of two or more stereoisomeric substrates) and (ii) product stereoselectivity (the differential formation of two or more stereoisomeric metabolites from a single substrate). Combinations of the two categories exist as (iii) substrate-product stereoselectivities, meaning that product stereoselectivity itself is substrate stereoselective. Here, published examples of metabolic stereoselectivities are examined in the light of these concepts. In parallel, a graphical scheme is presented with a view to facilitate learning and help researchers to solve classification problems.
Collapse
Affiliation(s)
- Bernard Testa
- Department of Pharmacy, Lausanne University Hospital , Lausanne , Switzerland
| |
Collapse
|
15
|
|
16
|
Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology 2009; 17:275-342. [DOI: 10.1007/s10787-009-0016-x] [Citation(s) in RCA: 256] [Impact Index Per Article: 17.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2009] [Accepted: 09/04/2009] [Indexed: 12/26/2022]
|
17
|
Chang SY, Li W, Traeger SC, Wang B, Cui D, Zhang H, Wen B, Rodrigues AD. Confirmation That Cytochrome P450 2C8 (CYP2C8) Plays a Minor Role in (S)-(+)- and (R)-(-)-Ibuprofen Hydroxylation in Vitro. Drug Metab Dispos 2008; 36:2513-22. [DOI: 10.1124/dmd.108.022970] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
|